What's Going On With TG Therapeutics Stock Wednesday?
What's Going On With TG Therapeutics Stock Wednesday?
Furthermore, the data showed that after five years of continuous treatment 17% of patients achieved confirmed disability improvement for at least 24 weeks. Eight percent of patients experienced confirmed disability progression for at least 24 weeks following five years of treatment.TG Therapeutics, Inc. (NASDAQ:TGTX) stock is trading higher on Wednesday after the company announced it updated its data presentations to include details from the ULTIMATE I & II Phase 3 trials, evaluating BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis.
TG Therapeutics, Inc. (納斯達克:TGTX)股價在週三交易高開，原因是該公司宣佈更新數據報告，包括ULTIMATE I和II階段3臨床試驗的細節，評估BRIUMVI (ublituximab-xiiy)在複發性多發性硬化患者中的應用。
The Details: The data was shared at the 2024 European Committee for Treatment and Research in Multiple Sclerosis annual meeting, with the presentations also accessible online.
具體資料：數據在2024年歐洲多發性硬化治療與研究委員會年會上共享，並可在線查看演示文稿。
The data indicated that continued use of BRIUMVI resulted in decreasing annualized relapse rates. Specifically, at year three, the annualized release rate was 3.2%, but at year five the annualized relapse rate was 2%.
數據表明，持續使用BRIUMVI導致年複發率下降。具體而言，第三年的年複發率爲3.2％，而第五年的年複發率爲2％。
Furthermore, the data showed that after five years of continuous treatment 17% of patients achieved confirmed disability improvement for at least 24 weeks. Eight percent of patients experienced confirmed disability progression for at least 24 weeks following five years of treatment.
此外，數據顯示，在持續治療五年後，有17％的患者獲得了至少24周的經確認的殘疾改善。8％的患者在接受五年治療後至少24周經確認的殘疾進展。
In addition, the safety profile of BRIUMVI remained stable over five years of continuous treatment.
此外，BRIUMVI的安全性在持續治療五年後仍然穩定。
"These data demonstrate that patients treated with BRIUMVI for up to 5 years had sustained clinical benefit, including further reductions in the risk of relapse in later years of treatment and an impressively low rate of confirmed disability progression," said CEO and chairman of TG Therapeutics Michael Weiss.
TG Therapeutics首席執行官兼董事長Michael Weiss表示：「這些數據表明，接受BRIUMVI治療多達5年的患者獲得了持續的臨床效益，包括治療後幾年的復發風險進一步降低和經確認的殘疾進展率驚人地低。」
TGTX Price Action: At the time of publication, TG Therapeutics stock is moving 1.52% higher at $25.46 per data from Benzinga Pro.
TG Therapeutics股票價格行動：根據Benzinga Pro的數據，發佈時，TG Therapeutics股票價格上漲1.52％，達到25.46美元。
Image: Photo by roberto-sorin for Unsplash
圖片：由roberto-sorin提供的Unsplash
譯文內容由第三人軟體翻譯。
